Legal Action News

Your news source for lawsuits and other civil legal matters

Legal Action Recently...

April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004


Legal Action News RSS Feed
RSS Feed



 

Shareholder Class Action Filed Against Atherogenics, Inc. - AGIX

16 January 2005

Murray, Frank & Sailer LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, civil action number 05-cv-61, on behalf of shareholders who purchased or otherwise acquired the securities of Atherogenics, Inc. ("AGIX" or the "Company") (Nasdaq:AGIX) between September 28, 2004 and December 31, 2004, inclusive (the "Class Period").

The complaint charges AGIX, Russell Medford, Mark Colonnese, and Robert Scott with violations of United States securities laws. More specifically, the Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them: (1) that the Company hyped the results of an inconclusive and limited study of AGI-1067; (2) that the statistically impressive levels of plaque reduction, described by AGIX in the initial announcement, varied significantly from the results achieved by the Cleveland Clinic; (3) that the Company was burning cash at a high rate; and (4) that the Company manipulated the study's results in order to enter into a strategic partnership with a major pharmaceutical company to complete the development and commercialization of AGI-1067.

Murray, Frank & Sailer LLP and its predecessor firms have devoted its practice to shareholder class actions and complex commercial litigation for more than thirty years and have recovered hundreds of millions of dollars for shareholders in class actions throughout the United States.

If you purchased or otherwise acquired Atherogenics securities on any world exchange between September 28, 2004 and December 31, 2004, and sustained damages, you may, no later than March 6, 2005, move the Court to serve as lead plaintiff. Shareholders outside the United States may also join the action, regardless of which exchange was used to purchase the securities. To serve as lead plaintiff, however, you must meet certain legal requirements. You can join this class action as lead plaintiff online at http://www.murrayfrank.com/CM/NewCases/NewCases.asp. If you would like to discuss this action, this announcement, or your rights and interests, please contact plaintiff's counsel Eric J. Belfi or Aaron D. Patton of Murray, Frank & Sailer LLP.

More information on this and other class actions can be found on the Class Action Newsline at www.primezone.com/ca

CONTACT: Murray, Frank & Sailer LLP
Eric J. Belfi
Aaron Patton
(800) 497-8076
(212) 682-1818
Fax: (212) 682-1892
Email: info@murrayfrank.com


Source: PrimeZone


All trademarks and copyrighted information contained herein are the property of their respective owners.

 
Law News



A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z